OUR TEAMImplicit Bioscience is founded upon the principle that quality people drive success and create value
Director & Chairman, Australia
Professor Andrews joined the Implicit Board in April 2004. He is an eminent Queensland scientist with a research career in molecular design, intermolecular interactions, drug structure-activity relationships, and molecular diversity. As a bio-entrepreneur with extensive understanding of the policy and economic development issues associated with science, research and innovation, he has led multi-functional scientific teams at research institutions in Victoria and Queensland, where together with Professor John Mattick AO, he established Queensland’s Institute for Molecular Bioscience (2000).
His other achievements include the development of major research facilities at the Victorian College of Pharmacy (1980-1987), Bond University (1988-1990) and the Centre for Drug Design and Development (3D Centre) at the University of Queensland (1991-1999). He established the first Australian laboratory in the field of computer-assisted drug design at the John Curtin School of Medical Research (Australian National University) in 1975. Peter has been at the forefront of initiatives to develop the Australian biotechnology industry and is active and vocal on the commercialisation of Australian science and research. Since 1985, he has founded or co-founded a number of scientific companies including Implicit Bioscience, Alchemia and Biota, developers of anti-influenza drug Relenza. He has served as Queensland’s Chief Scientist and is a director of several companies in the life and agricultural science industries.
Director and Chairman, USA
Jim Rottsolk has served as the Chairman and a director of Implicit Bioscience, Inc., the Seattle-based subsidiary of Implicit Bioscience Ltd., since 2012. Jim was the cofounder of Cray Inc., the global supercomputing leader, and served as its Chairman and CEO from 1987 to 2005.
Cray has grown from its founding in Seattle to over 1,000 employees in offices throughout the world and a market capitalization well in excess of $1 billion.
Jim Rottsolk earned both A.M. and J.D. degrees from the University of Chicago. Prior to entering the computer technology business, Jim was a partner in the law firm of Stoel Rives. Subsequent to his retirement from Cray, Jim spent four years at Microsoft Research in advanced technology and technology policy positions.
Chief Executive Officer and Managing Director
Garry is a co-founder of Implicit Bioscience and has been in leadership positions in the Australian biotechnology sector since 1999 when he co-founded Peplin Ltd. As CEO, he led Peplin through its IPO on the ASX and negotiated its licensing deal with US dermatology company Allergan, which was the first ever out-licensing of an Australian anti-cancer drug to a US pharmaceutical company. Following completion of Phase 2 clinical development, Peplin was ultimately sold in 2009 to Danish pharmaceutical company Leo Pharma AS for $297m, and the drug which commenced development under his leadership is now registered in all key international markets as Picato™.
Originally a commercial lawyer, Garry holds BA and LLB degrees from the University of Queensland. He has advised the Prime Minister’s Science Innovation and Engineering Council and has been a Governor-in-Council appointee to the Council of Griffith University since 2003.
Garry is a Director of both Implicit Bioscience, Inc. and Implicit Bioscience Ltd.
Director; Chairman, Scientific Advisory Board
Ian Frazer has been an investor and chief scientist of Implicit Bioscience since foundation. As co-inventor of the cervical cancer vaccines Gardasil™ and Cervarix™, Ian Frazer is one of Australia’s most celebrated medical research scientists and holds research funding from several Australian and US funding bodies. He is immediate past president of the Cancer Council Australia and chair of the International Agency for Research on Cancer Scientific Advisory Committee. He advises the World Health Organisation and the Bill and Melinda Gates Foundation on papillomavirus vaccines. He won the 2005 CSIRO Eureka Prize for Leadership in Science, was the Australian of the Year in 2006, and won the Prime Minister’s Prize for Science in 2008. He was the foundation CEO and Director of Research of the Translational Research Institute until 2015, and now chairs the TRI Foundation Board.
In May 2011, Prof Frazer was elected as a Fellow of the Royal Society of London, joining such world renowned scientists as Stephen Hawking and Sir Isaac Newton. In 2012, Professor Frazer was appointed a Companion of the Order of Australia (AC) in the Queen’s Birthday Honours. In 2016, Professor Frazer was appointed as Chair of the Medical Research Future Fund Advisory Board.
Daniel D. Syrdal joined the Seattle law firm of Heller Ehrman White & McAuliffe in 1988 and maintained an extensive life sciences and intellectual property transactions practice through to 2011. Dr. Syrdal spent several years in an in-house position with Cytran, Inc. where his responsibilities included identification and evaluation of technology, negotiation and implementation of joint ventures, licensing, development agreements and directing international research and development efforts for ODS in Russia.
Dan represented numerous biotechnology companies in the US, Australia, and New Zealand, assisting them with identifying, evaluating, and implementing licensing, research and development collaboration, partnering and funding opportunities, especially as these relate to international agreements. He has organized and participated in partnering and investment forums throughout Australia and New Zealand, and has advised federal and state governments in those countries regarding the development of their biotechnology industries, including assisting both government and private industry from these countries with contacts in the US biotechnology and capital investment industries.
Dan was a National Science Foundation Fellow and received his Ph.D. in organic chemistry and his Juris Doctor degrees from the University of Washington. Dan is also a Director of Implicit Bioscience Ltd.
Dr Huntsman was an early investor in Implicit Bioscience, Inc. and has served on the group’s US board of directors since 2013. After distinguished service in academic leadership spanning more than two decades including his time as President and Provost of the University of Washington, Lee Huntsman was named President Emeritus by the University Board of Regents in July 2004. UW consistently ranks in the top five research universities in the US and in the top ten world-wide. From 2005 to 2012, Dr Huntsman also served as the first executive director of the Life Sciences Discovery Fund Authority, a public-private partnership intended to advance life sciences research in the state.
His passion for interdisciplinary research is currently focused on exploring ways in which the state and the research community can become more agile and successful in the reinvention of health care.
Dr. Huntsman has been elected Fellow of the American Institute of Medical and Biological Engineering, the Biomedical Engineering Society and the American Association for the Advancement of Science.
Mr Lemay is an entrepreneur, educator and philosopher with a background in waste management and investment in the Seattle area. Originally a high-school art teacher, Norm went on to transform his family’s waste management business into an asset worth more than $300M and has become a significant investor in Implicit Bioscience, Inc. He is a successful author and public speaker and serves on a number of industry and company boards in the USA.
Chief Financial Officer and Secretary
Marion joined Implicit Bioscience in late 2012 and was appointed to her present position one year later. She has held finance roles of increasing seniority in companies in Australia and overseas, including at an ASX-listed biotechnology company. Marion is a qualified CPA in Australia, and a certificated member of the Governance Institute of Australia. She holds an Honours degree in Genetics, and qualified as a Chartered Accountant in the UK.
Research & Development
David is an accomplished cell and molecular biologist with experience leading drug discovery and development teams in target selection, validation, lead optimization, and pre-clinical development. His experience in autoimmune, fibrotic, and oncology indications has seen him in senior leadership positions in a US biotech company and two Seattle-based biotech start-ups.
Mark is an immunologist with 20 years’ experience working in early stage target discovery and development in the biopharmaceutical industry.
He has worked in a variety of settings ranging from start-up environments through established global pharmaceutical companies and has led programs across research sites around the globe and between industrial and academic partners. Most recently he was a founding member of the target discovery and validation group at Novo Nordisk in Seattle where he was responsible for the identification and implementation of discovery strategies in autoimmune disease and diabetic complications, and for the evaluation and management of external collaborations with industrial and academic partners.
Chief Business Officer
Brian is a medical product marketing and commercialisation specialist with experience in both the medical device and pharmaceuticals industry. Since transitioning from academia (tissue engineering), Brian has worked exclusively in small medium enterprise biotechnology companies. Brian’s skill set evolved in the adaptive start-up environment and includes product innovation & development, business development, marketing, market access, product management, regulatory affairs support, supply chain development, technical sales, budgeting and planning. This broad skill set positions Brian to support partnering and business development activities at Implicit Bioscience.